 |
7 Diseases |  |
0 Trials |
|
0 Trials |  |
13 News |  |
- | AZD9056 / AstraZeneca
Journal: P2X signaling influences the production of pro-resolving and pro-inflammatory lipid mediators in alveolar macrophages derived from individuals with asthma. (Pubmed Central) - Aug 15, 2023
The early production of the pro-resolving eicosanoids, LXA4 and Resolvin D1, is regulated by P2X, whereas generation of the pro-inflammatory eicosanoid, 15(S)-HETE, is only partially regulated through P2X signaling and reaches maximal production after the peak in pro-resolving eicosanoids.
- | Vampex (carbenoxolone gel) / York Pharma, AZD9056 / AstraZeneca
Journal: Caspase-11 promotes NLRP3 inflammasome activation via the cleavage of pannexin1 in acute kidney disease. (Pubmed Central) - Mar 19, 2022
The above results demonstrate that the cleavage of panx1 by upregulated caspase-11 is involved in facilitating ATP release and then NLRP3 inflammasome activation in I/R-induced AKI. This study provides new insight into the molecular mechanism of NLRP3 inflammasome activation in AKI.
- AZD9056 / AstraZeneca
Purinergic Receptor Activation Stimulates Lipoxin A4 Production in Alveolar Macrophages Derived from Individuals with Asthma (Room 303-304 (South Building, Level 3), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_3986;
Both early and late production of LXA4 by alveolar macrophages is regulated by P2X7, whereas generation of 15(S)-HETE and PGE2 is only partially regulated through P2X7 signaling in these cells. Imbalances in eicosanoid production by alveolar macrophages may explain failure of exacerbation resolution in a subset of patients.
- | AZD9056 / AstraZeneca
Journal: AZD-9056, a P2X7 receptor inhibitor, suppresses ATP-induced melanogenesis. (Pubmed Central) - Jun 22, 2021
Imbalances in eicosanoid production by alveolar macrophages may explain failure of exacerbation resolution in a subset of patients. No abstract available
- AZD9056 / AstraZeneca
[VIRTUAL] P2X7 Receptor Activity Mediates Th17-Specific Self- and Alloreactivity in Non-Human Primates () - May 18, 2021 - Abstract #ATC2021ATC_1754;
Importantly, by revealing functional polymorphisms consistent with human variations, we validated their rigor as a preclinical model for P2X7R-targeted therapies. Based on these findings, we hypothesize that low pore activity is associated with a tolerogenic state and that P2X7R inhibition could enhance tolerance induction protocols.
- | quercetin (LY294002) / Eli Lilly, AZD9056 / AstraZeneca
Journal: PI3K/Akt/GSK-3β signal pathway is involved in P2X7 receptor-induced proliferation and EMT of colorectal cancer cells. (Pubmed Central) - Mar 20, 2021
P13/Akt pathway inhibitor LY294002 inhibited the proliferation of CRC cells, and the P13/Akt signaling was required for BzATP induced the proliferation of CRC cells. Our conclusion is that P2X7R mediated the PI3K/Akt/GSK-3beta signaling to promote the proliferation and EMT of CRC, indicating that P2X7R may be used as a potential therapeutic target for CRC.
- | AZD9056 / AstraZeneca
Journal: Activation of P2×7 Receptor Promotes the Invasion and Migration of Colon Cancer Cells via the STAT3 Signaling. (Pubmed Central) - Dec 19, 2020
The results showed that ATP and BzATP significantly increased the inward current and intracellular calcium concentration of LOVO and SW480 cells, while the use of antagonists (A438079 and AZD9056) could reverse the above phenomenon...Our conclusion is that ATP-induced P2 × 7 receptor activation promotes the migration and invasion of colon cancer cells, possibly via the activation of STAT3 pathway. Therefore, the P2 × 7 receptor may be a potential target for the treatment of colon cancer.